Icon

Zohydro ER - (10,15,20,30,40,50 mg; Capsule, Extended Release)

Hydrocodone Bitartrate PERNIX IRELAND
10,15,20,30,40,50 mg; Capsule, Extended Release
Less Than $1000 mn
Less Than 5
Less Than 5
None
Less Than 5
Less Than 5
None
Indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Yes
****** (*******) & ******* *** *** ***** ** **** **** ** **** ******* '***, '*** (**** ******** ** *** *, ****); '*** (*** **, ****) *** *** ************ *********. ** ****** **** **** *** ********* **** *******. ****** *** **** ***** *** **** ****** ** *** **** *** ******* **** ****** ** *****(********) ***. ’*** (**** **, ****), ’***(**** **, ****), ’***(**** **, ****), ’***(**** **, ****), ’***(**** **, ****), *** ’*** (**** **, ****). ********** *** ********* **** ******* *** *** *** ******* ***** *** ***** ** ********* *** *** *****. ********** ********* **** *******.
Zohydro ER Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16 Patent 17
******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *******
******* ******* ******* ******* ******* ***** *** ** ** ******* ******* ******* ***** *** ** ** **** ** *** **, **** **** ** *** **, **** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** ***** *, **** ******* ********* ******** ** ***** *, ****
******* *** \ ** ***** *, **** **** ******* *** ** ** ******** ******** ** *** **, ****
  1. *** **, **** : ******* & ******* ********** ******** ***** ****** **** ** ***** **** ** **** ******* '***, '*** (**** ******** ** *** *, ****).
  2. *** **, **** : ***** ***** ***** ******* ******* & ******* ** ******** ***** ** ********.
  3. *** **, **** : ******* & ******* ********** ******** ***** ***** *** **** ** **** ****** '*** (*** **, ****).
  4. *** **, **** : ***** ***** * **** ******* ******* ** ******** ***** ** ********.
  5. *** **, **** : *******’*** (**** **, ****), ’***(**** **, ****), ’***(**** **, ****), ’***(**** **, ****), ’***(**** **, ****), *** ’*** (**** **, ****) **** ****** ** *****.
  6. *** **, **** : ***** ***** * **** ******* ******* *** ******* *** ******* ’*** (**** **, ****), ’***(**** **, ****), ’***(**** **, ****), ’***(**** **, ****), ’***(**** **, ****), *** ’*** (**** **, ****).
  7. *** *, **** : ******* *** ********* ********
  8. *** **, **** : ******* *** ********* ********. *****://***.**********.***.***/**********_****/*********/****/********************.***
  9. *** **, **** : ********** ********* **** ******* *** *** *** ******* ** ****. ********* ** ********** ******* *** ****** ******* ** ***** *, ****.
  10. *** **, **** : ***** **** * ********** ******* **** ****** '*** & '*** *** *** ******* *** *** *** *********
  11. *** **, **** : ******* *************** *** ******** **** *** *** **** ******* ******* **** ******* ** ******* *********** ********** ********-******* ******** ** ******* *** ****** ** ******** **** ******* **********
  12. *** **, **** : ******* ******* ******* ******* *****'* ******** **** '*** & '*** ******* *** *** ********* ** *******.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.